Mazdutide

A GLP-1/glucagon co-agonist based on oxyntomodulin, developed largely through trials conducted in China.

Mazdutide is classified as a dual glp-1/glucagon receptor agonist. Its current development status is: phase 3 clinical trials. Human trial data exists but is limited in size, duration or independence; conclusions should be held loosely.

The Peptide Institute tracks Mazdutide because it is actively sold through research-compound and telehealth channels. Our interest is narrow and specific: what is actually in the vial, whether the label is accurate, and whether the sellers of it can document what they claim. We take no position on whether anyone should use it.